STOCK TITAN

Davita Inc Stock Price, News & Analysis

DVA NYSE

Welcome to our dedicated page for Davita news (Ticker: DVA), a resource for investors and traders seeking the latest updates and insights on Davita stock.

DaVita Inc. (NYSE: DVA), a Fortune 500 leader in kidney care and dialysis services, maintains this dedicated news hub for stakeholders tracking its clinical advancements and financial performance. Access consolidated updates on earnings reports, strategic partnerships, and regulatory developments shaping the company’s position in global healthcare markets.

This resource serves investors and industry observers seeking timely insights into DaVita’s operational milestones, including innovations through DaVita Clinical Research and expansions of its integrated care network. Content spans press releases on treatment protocols, Medicare reimbursement updates, and collaborations with healthcare providers.

Key categories include quarterly financial disclosures, acquisitions in outpatient care, clinical trial outcomes, and quality improvement initiatives. Bookmark this page for streamlined access to verified updates about DaVita’s efforts to advance kidney disease management across 3,000+ U.S. dialysis centers.

Rhea-AI Summary

DaVita Inc. appointed Dr. Gregory Moore as an independent director effective Sept. 9, 2021. With nearly 20 years of healthcare experience, Dr. Moore currently leads Microsoft's Health & Life Sciences division, focusing on digital transformation in healthcare. CEO Javier Rodriguez emphasized that Dr. Moore's expertise will enhance DaVita's efforts to innovate kidney care solutions. Dr. Moore will participate in the Nominating and Governance Committee and the Compliance and Quality Committee. This addition strengthens the Board's diversity, with 33% racial/ethnic and 44% gender representation.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.68%
Tags
management
-
News
Rhea-AI Summary

DaVita reported strong financial results for Q2 2021, with diluted earnings per share of $2.64, a 63% increase year-over-year. Consolidated revenues reached $2.917 billion, while operating income was $490 million. The company experienced a solid operating cash flow of $680 million and free cash flow of $503 million. DaVita's ongoing investment in integrated kidney care is expected to drive growth, increasing patients under value-based care arrangements to approximately 10% of its U.S. dialysis patient base. The company also repurchased over 2 million shares this quarter.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.63%
Tags
none
-
Rhea-AI Summary

DaVita Inc. (NYSE: DVA) announced a quarterly conference call to discuss its second quarter results on August 3, 2021, at 5:00 p.m. Eastern Time. The results will be released after market close on the same day. Investors can join the call via phone or webcast. DaVita is focused on improving kidney care services, treating patients with chronic kidney failure, and has become the leading provider of home dialysis in the U.S., serving over 202,600 patients across 2,827 outpatient dialysis centers.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.58%
Tags
none
Rhea-AI Summary

DaVita and the National Kidney Foundation (NKF) have partnered to launch a yearlong pilot program aimed at enhancing health equity in kidney transplantation. This initiative will be implemented in Colorado, New York, Minnesota, and New Mexico, focusing on empowering kidney patients to find living donors. The program will offer extensive support, including one-on-one guidance from Patient Navigators and access to a new web platform for education. With over 500,000 individuals in the U.S. living with kidney failure and nearly 100,000 awaiting a transplant, this collaboration seeks to improve donor accessibility and patient outcomes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.13%
Tags
none
-
Rhea-AI Summary

On June 2, 2021, DaVita Kidney Care launched virtual support groups via its DaVita Care Connect platform, aimed at enhancing community among home dialysis patients. These sessions, facilitated by home support specialists, provide a space for live discussions on topics such as stress management and the path to kidney transplants. Over 50% of DaVita's home patients currently utilize digital platforms for care. This initiative reflects DaVita's commitment to improving the home dialysis experience and fostering patient connection.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.21%
Tags
none
-
Rhea-AI Summary

DaVita Kidney Care announced the recognition of 60 nephrology nurses with The DAISY Award during National Nurses Week. This award celebrates the extraordinary care these nurses provide to patients. Each honoree received a personalized certificate, a DAISY Award pin, and a hand-carved sculpture. DaVita, one of the largest kidney care service providers in the U.S., serves over 202,600 patients across 2,827 outpatient dialysis centers. The company is committed to improving patient care through innovative practices and reducing hospitalizations.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.57%
Tags
none
Rhea-AI Summary

DaVita Kidney Care announced the expansion of its home kidney care program with the HomeChoice Claria Automated Peritoneal Dialysis (APD) system, enhanced by Sharesource remote patient monitoring technology from Baxter International. This initiative aims to empower patients to manage kidney failure at home, offering improved connectivity between patients and care teams. Currently, DaVita is utilizing this technology with over 250 patients across the U.S., focusing on enhancing the quality of life for individuals undergoing peritoneal dialysis.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.93%
Tags
none
-
News
Rhea-AI Summary

DaVita reported Q1 2021 results showing diluted EPS from continuing operations at $2.09, a 15.5% increase YoY. Consolidated revenues reached $2.820 billion, while operating income was $443 million. Operating cash flow fell to $154 million, and free cash flow was negative at $(17) million, impacted by COVID-19. The company repurchased nearly 3 million shares at an average cost of $109.28. Although the pandemic posed challenges, DaVita successfully vaccinated nearly 75% of its U.S. dialysis patients, enhancing health equity.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.8%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.87%
Tags
none
Rhea-AI Summary

DaVita Inc. (NYSE: DVA) announced a quarterly conference call to discuss its first-quarter results on April 29, 2021, at 5:00 p.m. Eastern Time. The financial results will be released after market close on the same day. Investors can access the call via dial-in or webcast and must provide the password "Earnings" during the call.

DaVita is a leading healthcare provider focused on kidney care, serving over 204,200 patients at 2,816 outpatient dialysis centers in the U.S. It also operates facilities in ten countries, emphasizing patient-centric care models and technological integration.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.02%
Tags
none

FAQ

What is the current stock price of Davita (DVA)?

The current stock price of Davita (DVA) is $137.84 as of June 16, 2025.

What is the market cap of Davita (DVA)?

The market cap of Davita (DVA) is approximately 10.4B.
Davita Inc

NYSE:DVA

DVA Rankings

DVA Stock Data

10.41B
38.12M
48.62%
49.83%
5.69%
Medical Care Facilities
Services-misc Health & Allied Services, Nec
Link
United States
DENVER